Alterity Therapeutics Limited (ASX:ATH)
Australia
· Delayed Price · Currency is AUD 0.0080
+0.0010 (14.29%)
Mar 9, 2026, 4:10 PM AEST
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 2.80M AUD in the half year ending December 31, 2025, with 47.49% growth. This brings the company's revenue in the last twelve months to 6.64M, up 78.18% year-over-year. In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M with 35.32% growth.
Revenue (ttm)
6.64M
Revenue Growth
+78.18%
P/S Ratio
13.11
Revenue / Employee
737.38K
Employees
9
Market Cap
87.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Imugene | 3.94M |
| Radiopharm Theranostics | 16.28M |
| Cynata Therapeutics | 1.69M |
| LTR Pharma | 1.13M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
Alterity Therapeutics News
- 9 hours ago - Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit - GlobeNewsWire
- 5 days ago - Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor - Nasdaq
- 7 days ago - Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics (ATHE) Advances Phase 3 Program with Strong Financials - GuruFocus
- 5 weeks ago - Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics (ATHE) Advances towards Phase 3 Trials with Promising MSA Treatment - GuruFocus
- 3 months ago - Alterity Therapeutics (ATHE) Pioneers Unique Approach to Neurodegeneration - GuruFocus
- 3 months ago - Alterity Therapeutics (ATHE) Focuses on Parkinson's Disease Research - GuruFocus